OncoMatch/Clinical Trials/Lymphoma — Diffuse Large B-Cell (DLBCL)
Lymphoma — Diffuse Large B-Cell (DLBCL) Clinical Trials
OncoMatch filters Lymphoma — Diffuse Large B-Cell (DLBCL) trials by the molecular markers that determine eligibility — MYC, BCL2, BCL6, CD274, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Lymphoma — Diffuse Large B-Cell (DLBCL) trials
These are the molecular markers most commonly required or evaluated in Lymphoma — Diffuse Large B-Cell (DLBCL) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Lymphoma — Diffuse Large B-Cell (DLBCL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma, Inc.
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Merck Sharp & Dohme LLC
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development, LLC
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Merck Sharp & Dohme LLC
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Genmab
How OncoMatch finds Lymphoma — Diffuse Large B-Cell (DLBCL) trials for you
AI reads the protocol
Every Lymphoma — Diffuse Large B-Cell (DLBCL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Lymphoma — Diffuse Large B-Cell (DLBCL) and mark your biomarker results — MYC, BCL2, BCL6 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.